Doximity (NYSE: DOCS) experienced a remarkable stock surge on Friday, with shares climbing 32.5% to $27.40, adding approximately $1.2 billion to its market capitalization. The rally, which saw trading volume reach 65.3 million shares, came despite the company issuing fiscal 2027 adjusted EBITDA guidance below expectations. The stock finished the week up 31.0%.
The market's enthusiasm was driven by optimism around Doximity's artificial intelligence initiatives, even as the company's financial outlook painted a mixed picture. While the midpoint of fiscal 2027 revenue guidance was raised by just $6 million to $676 million, the adjusted EBITDA midpoint fell by $10 million to $319 million. This divergence highlights the market's willingness to look beyond near-term profitability in favor of long-term AI-driven growth prospects.
The valuation bridge underscores this sentiment: for every additional dollar of revenue guidance, nearly $200 in equity value was added. The basic equity value/revenue multiple expanded from 5.5 times to 7.2 times, reflecting investor expectations of AI-related earnings potential beyond the current fiscal year.
Mixed Fiscal First-Quarter Results
Doximity's fiscal first-quarter results were a blend of beats and misses. Revenue came in at $156.6 million, surpassing consensus estimates by 3.2%, but non-GAAP diluted EPS of $0.29 fell a cent short of expectations. Adjusted EBITDA declined 6% year-over-year to $74.8 million, with the margin contracting to 47.7% from 54.7%. GAAP gross margin also slipped to 84.9% from 89.2%, and free cash flow dropped 34% to $39.6 million.
The increased costs are largely attributed to AI investments. Research expenses surged 44%, and share-based compensation jumped 68%. The company also reported higher hosting and software costs tied to AI-related projects.
AI Initiatives and Usage Trends
CEO Jeff Tangney highlighted Doximity's AI progress, noting that Doximity Ask ranked as the top-performing U.S.-based model in the NOHARM benchmark. He also emphasized that AI Search's revenue per query was more than ten times its current running cost, though he clarified this was a unit-economics figure, not an operating-margin metric.
Usage trends support the AI narrative: quarterly active workflow providers grew approximately 32% year-over-year, and AI Search queries jumped over 25% quarter-over-quarter. The number of customers generating at least $500,000 annually rose to 127 from 119. However, net revenue retention declined to 107% from 118%, a point of concern.
Benchmark and Peer Comparison
The NOHARM benchmark results warrant careful interpretation. Doximity Ask had a severe-error rate of 4.8%, trailing AMBOSS LiSA's 2.9%. The July 13 preprint indicated no statistically significant differences among the four clinical retrieval-augmented systems evaluated.
Friday's rally outpaced other health-technology peers significantly. Tempus AI rose 12.9%, Phreesia gained 9.5%, Teladoc Health advanced 6.7%, and Veeva Systems climbed 5.8%. Doximity's 32.5% jump was nearly 20 percentage points ahead of the second-best performer.
Analyst Reactions and Outlook
Sell-side opinions remain divided. Piper Sandler raised its price target to $47 from $42, while Raymond James increased its target to $38 from $23. Morgan Stanley maintained its $35 target, and Evercore ISI lifted its target to $40 from $22. However, Bank of America Securities reaffirmed a Sell rating with a $20 target, and Barclays held its Hold rating with a $20 target.
Among 21 analysts covering the stock, there are eight Buy ratings, 12 Holds, and one Sell. The consensus price target of $28.88 implies just a 5.4% premium to Friday's closing price, suggesting limited upside in the near term.
Risks and Market Watch
Investors are monitoring several risks: AI sales are still nascent, but associated costs are already significant. Gross margin contracted, free cash flow declined, and net revenue retention slowed. The NOHARM study found no statistically significant differences among major clinical AI firms, which could temper expectations.
Trading at 7.2 times the revised revenue midpoint, any execution shortfall could unwind much of Friday's repricing. The cash market reopens Monday, August 10, with Doximity's annual meeting scheduled for August 27. Upcoming U.S. retail sales data for July will be released Friday at 8:30 a.m. EDT, providing additional macroeconomic context.
